Mammalian Cell Banking Industry Forecast to Hit $4.78 Billion by 2029 With a Strong 11.1% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Mammalian Cell Banking Market Covering 2025–2034?

The mammalian cell banking market size has shown rapid expansion in recent years. It is anticipated to increase from $2.82 billion in 2024 to $3.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.5%. The market’s historical growth can be attributed to the rising demand for monoclonal antibodies, an increase in biopharmaceutical R&D investment, the growth of regulatory requirements for GMP compliance, the rising adoption of mammalian expression systems, and the increasing approval of biologic drugs.

The mammalian cell banking market is anticipated to experience significant expansion over the next few years. It is projected to reach a value of **$4.79 billion** by **2029**, growing at a compound annual growth rate (CAGR) of **11.1%**. The expansion during this forecast period stems from factors such as increasing demand for cell and gene therapies, the growing adoption of personalized medicine, heightened investment in biomanufacturing infrastructure, the advancement of biosimilar and biobetter development, and a rise in pandemic preparedness and vaccine development initiatives. Prominent trends expected in the forecast period include the integration of automation and digital tracking, continuous technological advancements in cell culture, progress in regenerative medicine, the development of serum-free and protein-free media, and sophisticated cryopreservation and analytical technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp

What Are The Top Growth Drivers Impacting The Mammalian Cell Banking Market Outlook?

The increasing demand for cell-based therapies is projected to fuel the expansion of the mammalian cell banking market in the future. Cell-based therapies involve cutting-edge medical approaches that employ living cells, frequently altered or engineered, to repair, replace, or regenerate impaired tissues and organs, offering targeted interventions for numerous diseases. The need for cell-based therapies is growing as the rising prevalence of chronic and rare conditions creates an urgent requirement for more effective and precise treatment options. Mammalian cell banking supports these therapies by providing a reliable, standardized source of high-quality cells, ensuring consistency, safety, and scalability in the creation and manufacturing of regenerative treatments. For instance, in April 2024, the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, reported that the number of therapies across all clinical pipeline phases has grown since the end of 2023, with Phase I showing the strongest increase of 11% since before the fourth quarter of 2022. Therefore, the escalating demand for cell-based therapies is propelling the growth of the mammalian cell banking market.

What Are The Leading Segments Analyzed In The Mammalian Cell Banking Market?

The mammalian cell banking market covered in this report is segmented as

1) By Product Type: Master Cell Bank, Working Cell Bank

2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)

3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing

4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production

5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:

1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines

2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks

Which Trends Are Impacting The Mammalian Cell Banking Market?

Leading companies in the mammalian cell banking market are concentrating on creating advanced solutions, such as novel stable cell line systems. These efforts aim to boost cell line productivity, ensure enduring genetic stability, and optimize biopharmaceutical manufacturing processes. Stable cell line systems themselves consist of genetically engineered mammalian cells crafted to reliably produce a desired protein or therapeutic molecule across multiple generations, exhibiting robust genetic stability and consistent outcomes. An illustration of this progress is seen in August 2024, when WuXi Biologics, a biopharmaceutical firm based in China, introduced the WuXia293 Stable platform. This innovative HEK293-based stable cell line system was specifically designed for the creation and manufacture of challenging-to-express biologic molecules. Employing exclusive mammalian cell line development technology, the platform guarantees stable expression and uniform quality throughout extended cell passages. The WuXia293 Stable platform addresses deficiencies associated with conventional CHO cell systems, such as low yields and compromised quality, by delivering elevated protein titers, enhanced human-like glycosylation, and scalable production suitable for both clinical and commercial applications.

Which Key Players Are Driving Competition In The Mammalian Cell Banking Market?

Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S.A., Samsung Biologics Co. Ltd., CMIC Holdings Co. Ltd., WuXi Biologics Inc., Fujifilm Diosynth Biotechnologies Inc., Evotec SE, AGC Biologics Inc., CordenPharma International GmbH, GenScript ProBio Co. Ltd., Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, BioVectra Inc., Polpharma Biologics S.A., and Abzena plc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

Which Region Is Projected To Lead The Mammalian Cell Banking Market During The Forecast Period?

North America was the largest region in the mammalian cell banking market in 2024. The regions covered in mammalian cell banking report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Mammalian Cell Banking Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28262&type=smp

Browse Through More Reports Similar to the Global Mammalian Cell Banking Market 2025, By The Business Research Company

Cell Banking Outsourcing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-banking-outsourcing-global-market-report

Cell Cultures Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Cell Harvesting Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-harvesting-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795